Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V3HG
|
|||
| Former ID |
DNC000488
|
|||
| Drug Name |
CV-6504
|
|||
| Synonyms |
CV-6504; 117574-40-0; CV 6504; 2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone; 2,5-Cyclohexadiene-1,4-dione,2,3,5-trimethyl-6-(3-pyridinylmethyl)-; ACMC-20mn9v; AC1L3QEW; ZINC4541; SCHEMBL2715544; CTK4B0337; DTXSID80151827; IPGAFOVEIIWXFR-UHFFFAOYSA-N; EX-A2681; 6-(3-pyridylmethyl)-2,3,5-trimethyl-1,4-benzoquinone; 2,5-Cyclohexadiene-1,4-dione, 2,3,5-trimethyl-6-(3-pyridinylmethyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H15NO2
|
|||
| Canonical SMILES |
CC1=C(C(=O)C(=C(C1=O)C)CC2=CN=CC=C2)C
|
|||
| InChI |
1S/C15H15NO2/c1-9-10(2)15(18)13(11(3)14(9)17)7-12-5-4-6-16-8-12/h4-6,8H,7H2,1-3H3
|
|||
| InChIKey |
IPGAFOVEIIWXFR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 117574-40-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Target Info | Inhibitor | [1], [2] |
| BioCyc | Aspirin-triggered lipoxin biosynthesis | |||
| Resolvin D biosynthesis | ||||
| Leukotriene biosynthesis | ||||
| Lipoxin biosynthesis | ||||
| Aspirin triggered resolvin D biosynthesis | ||||
| Aspirin triggered resolvin E biosynthesis | ||||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Ovarian steroidogenesis | ||||
| Toxoplasmosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Arachidonic acid metabolism | ||||
| Eicosanoid Synthesis | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann Oncol. 2000 Sep;11(9):1165-70. | |||
| REF 2 | Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney Int. 1991 May;39(5):920-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.